REGENXBIO Inc. (RGNX) Stock Analysis
A live, multi-source view of REGENXBIO Inc. (RGNX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Sector: Healthcare · Industry: Biotechnology · United States · 371 employees · regenxbio.com
Key statistics · as of 2026-09-06
As of 2026-09-06, REGENXBIO Inc. (RGNX) had a market capitalization of $590.2M (forward -3.0) and a beta of 0.93; the shares traded in a 52-week range of $5.46 – $16.19 (-5.7% over the year).
- Market cap
- $590.2M
- Enterprise value
- $752.3M
- Forward P/E
- -3.0
- Price / book
- 6.75
- EPS (trailing)
- $-3.67
- EPS (forward)
- $-3.00
- Payout ratio
- 0.0%
- 52-week range
- $5.46 – $16.19
- 52-week change
- -5.7%
- Beta
- 0.93
- Average volume
- 2.0M
- Shares outstanding
- 66.0M
- Short % of float
- 13.14%
- Profit margin
- -112.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, REGENXBIO Inc. (RGNX) last closed at $8.56 (the last completed close before that scan).
Technicals at the scan: RSI 39 (neutral territory), price -12.5% versus its 20-day average, 20-day versus 50-day average spread -9.4%, MACD histogram -0.11.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 77/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RGNX; corporate insiders filed 2 buys and 0 sells (1 filer, latest disclosure 2026-08-27). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gregory Austin Ciongoli (2B/0S). Who is trading what
RapidTradeView pick record
RGNX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls REGENXBIO Inc. (RGNX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RGNX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.